Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Mesothelioma 3Endometrial Neoplasms 2Vulvar Neoplasms 1Uterine Cervical Neoplasms 1Thyroid Neoplasms 1Solid Tumors Harboring NTRK Fusion 1Solid Tumors 1Small Cell Lung Carcinoma 1Skin Neoplasms 1Salivary Gland Neoplasms 1Parotid Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Neuroendocrine Tumors 1Neoplasms 1Microsatellite Unstable Colorectal Cancer 1Microsatellite Instability 1Mesothelioma, Malignant 1Melanoma 1Lymphoma, Non-Hodgkin 1Lung Neoplasms 1Low-grade Glioma 1Locally Advanced Solid Tumors 1KRAS p.G12C Mutant Advanced Solid Tumors 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Cholangiocarcinoma 1Carcinoma, Transitional Cell 1Carcinoma, Small Cell 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1

Interventions

sotorasib 1Midazolam 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has announcements × KRAS p.G12C Mutant Advanced Solid Tumors × Other solid neoplasm × Clear all
NCT03600883 2026-03-16

A Phase 1/2, Study Evaluating the Safety, Tolerability, PK, and Efficacy of Sotorasib (AMG 510) in Subjects With Solid Tumors With a Specific KRAS Mutation (CodeBreaK 100)

Amgen

Phase 1/2 Active not recruiting
713 enrolled 1 FDA
Other solid neoplasm

KRAS p.G12C Mutant Advanced Solid Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡